Interim report January-September 2017: Continuing high growth and profitability

2017-11-02 - 08:30

Third quarter:

  •  Sales amounted to SEK 246 (210) million, corresponding to an increase of 17 percent in SEK. Sales growth was 20 percent in local currency and consisted in its entirety of organic growth.
  •  Operating income before depreciation and amortisation (EBITDA) amounted to SEK 98 (71) million, corresponding to a margin of 40 (34) percent.
  •  Net income amounted to SEK 65 (45) million, which gave earnings per share of SEK 2.98 (2.05).

January-September:

  •  Sales amounted to SEK 775 (605) million, corresponding to an increase of 28 percent in SEK. Sales growth was 27 percent in local currency of which 21 percent represented organic growth.
  •  Operating income before depreciation and amortisation (EBITDA) amounted to SEK 305 (207) million, corresponding to a margin of 39 (34) percent.
  •  Net income amounted to SEK 196 (131) million, which gave earnings per share of SEK 8.99 (6.03).

Gothenburg, November 2, 2017
VITROLIFE AB (publ)
Thomas Axelsson, CEO


Queries should be addressed to:
Thomas Axelsson, CEO, tel 46 31 721 80 01
Mikael Engblom, CFO, tel 46 31 721 80 14

This information is information that Vitrolife AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 8.30 am CET on November 2, 2017.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.